|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
45.11(B) |
Last
Volume: |
3,009,533 |
Avg
Vol: |
1,927,028 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
214,192 |
275,430 |
303,186 |
572,710 |
Total Sell Value |
$28,873,866 |
$36,403,178 |
$39,551,376 |
$69,690,287 |
Total People Sold |
7 |
9 |
14 |
15 |
Total Sell Transactions |
15 |
25 |
46 |
79 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-10-22 |
4 |
AS |
$570.00 |
$142,500 |
D/D |
(250) |
40,829 |
|
-26% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-10-15 |
4 |
AS |
$545.84 |
$3,295,334 |
D/D |
(6,000) |
90,705 |
|
-24% |
|
Patterson Chad |
EVP, Global Marketing |
|
2021-10-13 |
4 |
AS |
$545.54 |
$76,921 |
D/D |
(141) |
9,603 |
|
-25% |
|
Foletta Mark G |
Director |
|
2021-10-01 |
4 |
AS |
$538.02 |
$271,547 |
I/I |
(500) |
13,597 |
|
-24% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-09-23 |
4 |
AS |
$569.63 |
$3,866,020 |
D/D |
(6,743) |
41,079 |
|
-27% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-09-15 |
4 |
AS |
$536.49 |
$3,243,462 |
D/D |
(6,000) |
96,705 |
|
-28% |
|
Patterson Chad |
EVP, Global Marketing |
|
2021-09-13 |
4 |
AS |
$541.47 |
$84,469 |
D/D |
(156) |
9,744 |
|
-21% |
|
Flynn Paul R |
EVP, Global Revenue |
|
2021-09-10 |
4 |
AS |
$558.33 |
$349,515 |
D/D |
(626) |
10,928 |
|
-23% |
|
Selvaraj Shelly Ramasamy |
SVP Information Technology |
|
2021-09-10 |
4 |
AS |
$558.33 |
$380,223 |
D/D |
(681) |
13,014 |
|
-23% |
|
Blackford Quentin S. |
Chief Operating Officer |
|
2021-09-10 |
4 |
AS |
$558.33 |
$848,103 |
D/D |
(1,519) |
19,280 |
|
-23% |
|
Patterson Chad |
EVP, Global Marketing |
|
2021-09-09 |
4 |
S |
$541.36 |
$157,538 |
D/D |
(291) |
9,900 |
|
21% |
|
Flynn Paul R |
EVP, Global Revenue |
|
2021-09-09 |
4 |
AS |
$541.36 |
$407,106 |
D/D |
(752) |
11,554 |
|
-21% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-09-09 |
4 |
S |
$541.36 |
$683,747 |
D/D |
(1,263) |
47,822 |
|
21% |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2021-09-09 |
4 |
S |
$541.36 |
$683,748 |
D/D |
(1,263) |
69,322 |
|
21% |
|
Balo Andrew K |
* |
|
2021-09-09 |
4 |
AS |
$541.33 |
$3,060,337 |
I/I |
(5,597) |
7,553 |
|
-21% |
|
Balo Andrew K |
* |
|
2021-09-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,498 |
13,150 |
|
- |
|
Balo Andrew K |
* |
|
2021-09-09 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,498) |
14,056 |
|
-21% |
|
Abbey Donald |
EVP Quality and Regulatory Aff |
|
2021-09-09 |
4 |
S |
$541.36 |
$683,747 |
D/D |
(1,263) |
48,674 |
|
21% |
|
Selvaraj Shelly Ramasamy |
SVP Information Technology |
|
2021-09-09 |
4 |
AS |
$541.08 |
$1,214,059 |
D/D |
(2,223) |
13,695 |
|
-21% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-09-09 |
4 |
S |
$541.27 |
$1,633,280 |
D/D |
(3,017) |
102,705 |
|
21% |
|
Murphy Patrick Michael |
EVP, Chief Legal Officer |
|
2021-09-09 |
4 |
S |
$541.36 |
$534,327 |
D/D |
(987) |
16,254 |
|
21% |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2021-09-09 |
4 |
S |
$541.36 |
$220,336 |
D/D |
(407) |
13,526 |
|
21% |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2021-09-09 |
4 |
S |
$541.36 |
$220,339 |
D/D |
(407) |
12,234 |
|
21% |
|
Blackford Quentin S. |
Chief Operating Officer |
|
2021-09-09 |
4 |
AS |
$541.36 |
$5,178,699 |
D/D |
(9,462) |
20,799 |
|
-21% |
|
Blackford Quentin S. |
Chief Operating Officer |
|
2021-09-08 |
4 |
AS |
$545.87 |
$4,192,846 |
D/D |
(7,681) |
30,261 |
|
-21% |
|
2303 Records found
|
|
Page 12 of 93 |
|
|